Comparative Pharmacology
Head-to-head clinical analysis: CEQUA versus MYCOPHENOLATE MOFETIL HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEQUA versus MYCOPHENOLATE MOFETIL HYDROCHLORIDE.
CEQUA vs MYCOPHENOLATE MOFETIL HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Immunosuppressant; binds to cyclophilin D in mitochondria, inhibiting opening of mitochondrial permeability transition pore (mPTP), which reduces T-lymphocyte activation and cytokine release. Also forms complex with cyclophilin A to inhibit calcineurin, suppressing IL-2 production and T-cell proliferation.
Mycophenolate mofetil hydrochloride is a prodrug of mycophenolic acid (MPA), a selective, reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). This enzyme is crucial for de novo guanosine nucleotide synthesis in T and B lymphocytes, leading to inhibition of lymphocyte proliferation and antibody production.
Instill one drop of 0.09% ophthalmic solution in each eye twice daily, approximately 12 hours apart.
Oral: 1-1.5 g twice daily; intravenous: 1 g over 2 hours twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 8.4 hours (range 6-10 hours) in healthy adults; prolonged in hepatic impairment and pediatric patients.
The terminal elimination half-life of MPA is approximately 17.9 hours (range 11.7–30.9 hours) in healthy volunteers. In renal transplant patients, half-life may be prolonged to 16.6 ± 6.2 hours. This supports twice-daily dosing with monitoring of trough levels for efficacy and toxicity.
Primarily fecal (90%) with minor renal excretion (<1% unchanged drug). Biliary excretion is the major route for elimination of cyclosporine metabolites.
Mycophenolic acid (MPA), the active metabolite, is primarily excreted in urine as the glucuronide conjugate (MPAG). Approximately 87% of an administered dose is recovered in urine, with <1% as unchanged MPA. Fecal excretion accounts for about 6% of the dose, mainly as MPAG via biliary secretion.
Category C
Category D/X
Immunosuppressant
Immunosuppressant